Cipla Limited (CIPLA)

Price1,185.90 -20.50 (-1.70%)52 Week High1,277.90
ISININE059A0102652 Week Low852.00
IndustryPharmaceuticals: OtherVolume2.8 M
SectorHealth TechnologyP/E Ratio TTM30.77
Market Cap974.5 B1 Year Beta0.06
Technical Rating of

Cipla Limited (CIPLA) logo

Cipla Limited (CIPLA) is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It was founded in 1935 by Khwaja Abdul Hamied. CIPLA is one of the largest pharmaceutical companies in India and has a global presence, with operations in over 150 countries.

The company’s products include generic drugs, branded drugs, and over-the-counter (OTC) products. CIPLA’s generic drugs are available in a wide range of therapeutic categories, including anti-infectives, cardiovascular, respiratory, and anti-diabetics. The company’s branded drugs include products such as Cipramil (an antidepressant), Dolo 650 (a pain reliever), and Liv 52 (a liver tonic). CIPLA’s OTC products include products such as Vicks Vaporub (a cough suppressant) and Eno (an antacid).

CIPLA is a research-driven company and has a strong focus on innovation. The company has a number of research and development (R&D) facilities in India and abroad. CIPLA’s R&D efforts have resulted in the development of a number of new drugs, including the anti-cancer drug Infatinib.

CIPLA is committed to providing affordable healthcare to people around the world. The company has a number of programs in place to make its products accessible to people in low-income countries. CIPLA is also a member of the Access to Medicines Index, which is a global ranking of pharmaceutical companies based on their commitment to providing access to affordable medicines.

Here are some of the key facts about Cipla Limited:

  • Founded in 1935
  • Headquarters: Mumbai, India
  • Products: generic drugs, branded drugs, and OTC products
  • Revenue (FY 2022-23): ₹22,753 crores
  • Employees: 17,000
  • Market capitalization: ₹1.4 trillion
          

Cipla Limited (CIPLA) Chart

Technical Analysis of Cipla Limited (CIPLA)

Moving Averages

PeriodSimpleExponential
MA 51,221.611,213.85
MA 101,230.211,224.41
MA 201,234.661,226.40
MA 301,235.491,216.07
MA 501,189.921,184.05
MA 1001,080.371,120.54
MA 2001,036.271,069.18

Moving Average Rating

Technical Indicators

NameValueNameValue
Aroon Up (14)0.00Aroon Down (14)100.00
MACD Level (12, 26)5.14MACD Signal (12, 26)14.54
Relative Strength Index (7)20.20Relative Strength Index (14)37.61
Stochastic %D (14 3 3)26.24Stochastic %K (14 3 3)19.14
Stochastic RSI Fast (3, 3, 14, 14)7.78Stochastic RSI Slow (3, 3, 14, 14)15.22
Bollinger Upper Band (20)1,268.24Bollinger Lower Band (20)1,201.07
Keltner Channels Upper Band (20)1,277.91Keltner Channels Lower Band (20)1,174.88
Donchian Channels Upper Band (20)1,268.90Donchian Channels Lower Band (20)1,168.55
Ichimoku Conversion Line (9, 26, 52, 26)1,214.23Ichimoku Base Line (9, 26, 52, 26)1,218.73
Ichimoku Leading Span A (9, 26, 52, 26)1,186.21Ichimoku Leading Span B (9, 26, 52, 26)1,116.53
Positive Directional Indicator (14)17.73Negative Directional Indicator (14)25.88
Volume Weighted Average Price1,187.85Volume Weighted Moving Average 201,234.12

Oscillator Rating

Oscillators

Awesome Oscillator-10.54
Ultimate Oscillator (7,14,28)29.92
Money Flow (14)44.68
Chaikin Money Flow (20)-0.25
Commodity Channel Index (20)-278.60
Bull Bear Power-76.12

High / Low

1 Month1,268.901,168.55
3 Month1,277.90989.35
6 Month1,277.90876.05
52 Week1,277.90852.00
All Time1,277.9022.96

Volume

Volume2.8 M
Average 10 D1.7 M
Average 30 D1.6 M
Average 60 D1.9 M
Average 90 D1.8 M

Change/Volatility

Change-20.50 (-1.70%)
Change 1W-49.60 (-4.01%)
Change 1M-71.70 (-5.70%)
Volatility3.47
Volatility W2.29

Performance

Yesterday9.78
Weekly-3.96
Monthly-5.28
3 Month18.60
6 Month36.45
Yearly11.76
5 Year79.14
All Time5,026.37

Misc.

Average Day Range (14)23.71
Average Directional Index (14)41.43
Average True Range (14)25.81
Williams Percent Range (14)-82.38
Rate Of Change (9)-4.72
Hull Moving Average (9)1,210.93
Momentum (10)-63.40
Parabolic SAR1,262.10

PIVOT POINTS of Cipla Limited (CIPLA)

NameS3S2S1Pivot PointsR1R2R3
Classic972.701,100.601,179.101,228.501,307.001,356.401,484.30
Fibonacci1,100.601,149.461,179.641,228.501,277.361,307.541,356.40
Camarilla1,222.431,234.151,245.881,228.501,269.321,281.051,292.77
Woodie's1,073.051,111.531,200.951,239.431,328.851,367.331,456.75
DeMark's - - 1,203.801,240.851,331.70 - -

Financial Analysis of Cipla Limited (CIPLA)

Income Statement

Basic EPS (FY)34.72
Basic EPS (TTM)38.55
EBITDA (Annual YoY Growth)10.27
EBITDA (Quarterly QoQ Growth)27.28
EBITDA (Quarterly YoY Growth)30.66
EBITDA (TTM)53.8 B
EBITDA (TTM YoY Growth)23.61
EPS Diluted (Annual YoY Growth)11.30
EPS Diluted (FY)34.69
EPS Diluted (MRQ)12.33
EPS Diluted (Quarterly QoQ Growth)89.33
EPS Diluted (Quarterly YoY Growth)45.06
EPS Diluted (TTM)38.54
EPS Diluted (TTM YoY Growth)25.12
EPS Forecast (MRQ)12.24
Free Cash Flow (Annual YoY Growth)-11.15
Free Cash Flow Margin (FY)10.77
Gross Profit (Annual YoY Growth)11.85
Gross Profit (FY)80.5 B
Gross Profit (MRQ)27.9 B
Gross Profit (Quarterly QoQ Growth)17.82
Gross Profit (Quarterly YoY Growth)30.16
Gross Profit (TTM YoY Growth)18.79
Last Year Revenue (FY)227 B
Revenue (Annual YoY Growth)4.51
Revenue per Employee (FY)5.8 M
Revenue (Quarterly QoQ Growth)10.27
Revenue (Quarterly YoY Growth)17.74
Revenue (TTM YoY Growth)9.58
Net Income (Annual YoY Growth)11.33
Net Income (FY)28 B
Net Income (Quarterly QoQ Growth)89.42
Net Income (Quarterly YoY Growth)45.06
Net Income (TTM YoY Growth)25.03
Total Revenue (FY)227 B

Valuation

Enterprise Value/EBITDA (TTM)18.12
Number of Employees38,955.00
Number of Shareholders485.5 T
Shares Float498.3 M
Price to Book (FY)4.09
Price to Earnings Ratio (TTM)30.77
Price to Revenue Ratio (TTM)4.04
Price to Sales (FY)4.22
Total Shares Outstanding807.3 M
Research & development Ratio (FY)1.70
Research & development Ratio (TTM)5.98
Selling & Admin expenses Ratio (FY)15.40
Selling & Admin expenses Ratio (TTM)19.01

Balance Sheet

Total Assets (Annual YoY Growth)8.72
Total Debt (Annual YoY Growth)-23.93
Total Liabilities (FY)57.5 B
Cash & Equivalents (FY)6.4 B
Cash and short term investments (FY)62.8 B

Operating Metrics

Dividends

Dividend Yield Forward0.70
Dividends Paid (FY)-4,035,000,000.00
Dividends per share (Annual YoY Growth)70.00
Dividends per Share (FY)8.50

Margins

Net Margin (FY)12.34
Net Margin (TTM)13.12
Gross Margin (FY)35.44
Gross Margin (TTM)42.79
Operating Margin (FY)17.88
Operating Margin (TTM)17.80
Pretax Margin (TTM)18.72

Cipla Limited (CIPLA) FUTURES

ExpiryOpenHighLowCloseSettleContractsValueOIOI Change
28-Sep-231,208.351,209.951,169.001,189.201,189.204.9 T37.4 T10.4 M-258,700
26-Oct-231,215.051,215.051,176.251,196.801,196.802.1 T16.3 T788.5 T406.9 T
30-Nov-231,211.151,211.151,185.001,204.051,204.052620222.1 T3.9 T

Cipla Limited (CIPLA) OPTIONS

Related Companies (Peers) to Cipla Limited (CIPLA)

Price635.95 2.00 (0.32%)52 Week High775.45
ISININE098F0103152 Week Low554.05
IndustryPharmaceuticals: OtherVolume32,284
SectorHealth TechnologyP/E Ratio TTM43.12
Market Cap18.5 B1 Year Beta0.88
Technical Rating of
Amrutanjan Health Care Limited (AMRUTANJAN) is an Indian pharmaceutical company headquartered in Hyderabad, India. It was incorporated in 1965. The company’s initial focus was on the manufacturing of pain relief balms. Amrutanjan has since expanded its operations to include a wide range of over-the-counter (OTC) products, including cough syrups, cold remedies, and skin care products. more about Amrutanjan Health Care Limited (AMRUTANJAN)

Price866.40 -10.05 (-1.15%)52 Week High907.70
ISININE406A0103752 Week Low397.20
IndustryPharmaceuticals: OtherVolume1.4 M
SectorHealth TechnologyP/E Ratio TTM25.67
Market Cap513.3 B1 Year Beta0.66
Technical Rating of
Aurobindo Pharma Limited (AUROPHARMA) is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. It was founded in 1986 by P. V. Ramana Rao. Aurobindo’s initial focus was on the manufacturing of generic pharmaceuticals. It has since expanded its operations to include a wide range of products, including APIs, finished dosages, and biosimilars. Aurobindo is more about Aurobindo Pharma Limited (AUROPHARMA)

Price336.80 13.60 (4.21%)52 Week High381.00
ISININE101D0102052 Week Low267.75
IndustryPharmaceuticals: OtherVolume3.8 M
SectorHealth TechnologyP/E Ratio TTM18.89
Market Cap78.2 B1 Year Beta0.79
Technical Rating of
Granules India Limited (GRANULES) is a well-established company with a strong track record in the Indian pharmaceutical industry. The company is a leading manufacturer of active pharmaceutical ingredients (APIs) and finished dosages in India. GRANULES has a strong customer base in the Indian and global pharmaceutical markets. GRANULES is well-positioned to capitalize on the growing more about Granules India Limited (GRANULES)

Price1,097.45 -29.85 (-2.65%)52 Week High1,174.50
ISININE326A0103752 Week Low628.00
IndustryPharmaceuticals: OtherVolume1.3 M
SectorHealth TechnologyP/E Ratio TTM51.59
Market Cap513.9 B1 Year Beta0.46
Technical Rating of
Lupin Limited (LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It was founded in 1968 by Mr. Desh Bandhu Gupta. LUPIN is one of the largest pharmaceutical companies in India, with a market capitalization of over $20 billion. The company manufactures a wide range of generic and branded pharmaceutical products, including anti-infectives, more about Lupin Limited (LUPIN)

Price113.05 2.55 (2.31%)52 Week High155.90
ISININE933A0101452 Week Low88.50
IndustryPharmaceuticals: OtherVolume91,139
SectorHealth TechnologyP/E Ratio TTM
Market Cap3.7 B1 Year Beta0.96
Technical Rating of
Lyka Labs Limited (LYKALABS) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in 1990 by Mr. Rajesh Shah. LYKALABS is a leading manufacturer of generic APIs (active pharmaceutical ingredients) and finished dosage forms. The company’s products are used in a wide range of therapeutic areas, including anti-infectives, anti-diabetics, and cardiovascular drugs. more about Lyka Labs Limited (LYKALABS)

Cipla Limited (CIPLA) Related Indices

The Nifty 50 index is a well-diversified 50 companies index reflecting overall market conditions. Nifty 50 Index is computed using free float market capitalization method. Nifty 50 can be used for a variety of purposes such as benchmarking fund portfolios, launching of index funds, ETFs and structured products. Index Variants: Nifty50 USD, Nifty 50 Total Returns Index and Nifty50 Dividend Points Index more about Nifty 50

Nifty 100 is a diversified 100 stock index representing major sectors of the economy. Nifty 100 represents top 100 companies based on full market capitalisation from Nifty 500. This index intends to measure the performance of large market capitalisation companies. The Nifty 100 tracks the behavior of combined portfolio of two indices viz. Nifty 50 and Nifty Next 50. The Nifty 100 Index represents about 77% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016 of all index constituents is approximately 61% of the traded value of all stocks on the NSE. more about Nifty 100

The Nifty 200 Index is designed to reflect the behaviour and performance of large and mid market capitalization companies . Nifty 200 includes all companies forming part of Nifty 100 and Nifty Full Midcap 100 index. The Nifty 200 Index represents about 86% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 77% of the traded value of all stocks on NSE. more about Nifty 200

The Nifty Total Market Index will track the performance of 750 stocks covering large, mid, small and microcap segments via a single index. All stocks that are part of Nifty 500 index and Nifty Microcap 250 index form part of the Nifty Total Market index. Stock’s weight is based on its free-float market capitalization. more about Nifty Total Market

The Nifty 500 represents the top 500 companies based on full market capitalisation and average daily turnover from the eligible universe. It represents about 94% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all Index constituents is approximately 87% of the traded value of all stocks on NSE. more about Nifty 500

The Nifty500 Multicap 50:25:25 index aims to measure the performance of portfolio of large, mid and small market capitalisation companies with target weights assigned to each size segment. The Nifty500 Multicap 50:25:25 index includes all companies that are part of Nifty 500 index. While in Nifty 500 index, the total weight of each size segment (Large, Mid and Small cap) is based on the total free float market capitalisation of all stocks falling within that size segment, in Nifty500 Multicap 50:25:25 index, the total weight of each of these three segments (Large, Mid and Small cap) is fixed at 50%, 25% and 25% respectively at every quarterly rebalance date. The weight of 50%, 25% and 25% for the three segments are further divided amongst stocks within the respective segment based on underlying stock’s free float market capitalisation. Weight of each size segment may be different from its respective capped level between two rebalance dates due to price drift of underlying stocks. more about Nifty500 Multicap 50:25:25

The Nifty LargeMidcap 250 reflects the performance of a portfolio of 100 large cap and 150 mid cap companies listed on NSE, represented through the Nifty 100 and the Nifty Midcap 150 index respectively. The aggregate weight of large cap stocks and mid cap stocks is 50% each and are reset on a quarterly basis. The index has a base date of April 01, 2005 and a base value of 1000. The Index is reconstituted on a semi-annual basis along with Nifty 100 and Nifty Midcap 150 index. more about Nifty LargeMidcap 250

The Nifty Healthcare Index is designed to reflect the behaviour and performance of the Healthcare companies. The Nifty Healthcare Index comprises of maximum of 20 stocks that are listed on the National Stock Exchange. more about Nifty Healthcare

The Nifty Pharma Index is designed to reflect the behavior and performance of the pharmaceutical sector in India. more about Nifty Pharma

The Nifty India Manufacturing Index which aims to track the performance of the companies selected from the combined universe of Nifty 100, Nifty Midcap 150 and Nifty Smallcap 50 index based on 6 month average free-float market capitalisation within the eligible basic industries that broadly represent manufacturing sector. more about Nifty India Manufacturing

The Nifty100 Equal Weight Index comprises of same constituents as Nifty 100 Index (free float market capitalization based Index). As the name suggests, all stocks in Nifty 100 index are assigned equal weight at the time of rebalancing. more about Nifty100 Equal Weight

The Nifty100 Low Volatility 30 index tracks the performance of 30 stocks in Nifty 100 with the lowest volatility in last one year. Weights of securities in the index are assigned based on the volatility values. Security with lowest volatility in the index is assigned the highest weight. more about Nifty100 Low Volatility 30

The index is designed to reflect the performance of a portfolio of stocks selected based on top combination of Alpha, Quality and Low-Volatility. It intends to counter the cyclicality of single factor index strategy and provides investors a choice to take exposure to multiple factors through a single index product. The Index consists of 30 stocks selected from Nifty 100 and Nifty Midcap 50. more about Nifty Alpha Quality Low Volatility 30

The index is designed to reflect the performance of a portfolio of stocks selected based on top combination of Alpha, Quality, Value and Low-Volatility. It intends to counter the cyclicality of single factor index strategy and provides investors a choice to take exposure to multiple factors through a single index product. The Index consists of 30 stocks selected from Nifty 100 and Nifty Midcap 50. more about Nifty Alpha Quality Value Low Volatility 30

Nifty Growth Sectors 15 Index is designed to provide investors exposure to the liquid stocks from sectors of market interest. Sectors are first selected based on P/E and P/B values of Nifty sectoral indices, which are compared to Nifty 50 index. As a next step, companies with greater earnings per share (EPS) frequency are selected with preference given to companies with higher free-float market capitalization. more about Nifty Growth Sectors 15

Nifty Low Volatility 50 Index tracks the performance of the least volatile securities listed on NSE In order to make the 50 stock index investible and replicable, criteria’s such as turnover and free float market capitalization are applied while selection of securities. Weights of securities in the index are assigned based on the volatility values. Least volatile security in the index gets the highest weight. more about Nifty Low Volatility 50

The index is designed to reflect the performance of a portfolio of stocks selected based on top combination of Quality and Low Volatility. It intends to counter the cyclicality of single factor index strategy and provides investors a choice to take exposure to multiple factors through a single index product. The Index consists of 30 stocks selected from Nifty 100 and Nifty Midcap 50. more about Nifty Quality Low Volatility 30

Nifty50 Equal Weight Index represents an alternative weighting strategy to its market capitalization based parent index, the Nifty 50 Index. The index includes the same companies as its parent index, however, weighted equally. The index has a base date of November 03, 1995 and a base value of 1000. All constituents forming part of the Nifty 50 will form part of the index. more about Nifty50 Equal Weight

News Related to Cipla Limited (CIPLA)

  1. Sep 22, 2023, 9:04 pm

    Market Summary for September 22, 2023 Indian equity markets closed in the green on September 22, 2023, supported by buying in select banking and automobile stocks. Sectors such as pharma, information technology, and metals were the major drags. Options data suggests a sideways to positive momentum in the near term.

  2. Sep 22, 2023, 5:52 pm

    Indian market drops on September 22 despite inclusion of Indian bonds in JP Morgan index Indian benchmark indices Sensex and Nifty fell for the fourth consecutive day on September 22, despite the inclusion of Indian bonds in the JP Morgan Government Bond Index-Emerging Markets (GBI-EM) global index suite from June 2024. The market is expected to remain volatile in the near term, with key support at 19,600 for Nifty.

  3. Sep 22, 2023, 4:46 pm

    Pharma Sector Sees Bearish Sentiment on September 22 The pharmaceutical sector is experiencing bearish sentiment on September 22, with profit-booking pressure and short positions in several individual stocks, including Glenmark, Cipla, Alkem, and Dr Reddy's. Analysts believe that the Nifty Pharma Index could see further weakness if it breaks below the 14700-14800 support zone. On the other hand, Aurobindo Pharma is seen as a moderately bullish stock, with strong resistance at the 900 strike price and strong support at the 850 and 860 strike prices. Traders should be cautious and monitor the market closely for any further developments.

  4. Sep 21, 2023, 9:12 pm

    Indian markets fall for third straight day on September 21 Indian stock markets fell for the third consecutive day on September 21, tracking weak global cues. The US Federal Reserve maintained the status quo in its policy meeting but indicated that interest rates will remain higher for longer. This led to selling by foreign institutional investors (FII) and elevated crude oil prices remained a concern. Broader market performed even worse than the benchmark indices. All sectoral indices, barring Nifty Media, closed in the red. Nifty PSU Bank was the biggest loser during the day, falling 2.28 percent. Analysts believe that the market may remain volatile in the near term due to factors such as the hawkish stance by the US Fed, rising oil prices and erratic rainfall. However, they advise investors to stay stock-specific with a focus on risk management.

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Industries